Poster: Positive allosteric modulators of GABAA
Posted: 1 July 2016 | Charles River Laboratories | No comments yet
Selective and non-selective positive allosteric modulators were evaluated for their effects on GABAA α1β1γ2L and α1β2γ2L subtypes…
GABAA receptors are targets for drugs used for treatment of anxiety disorders.
Many of the drugs function as positive allosteric modulators (PAMs) of GABA, potentiating the inhibitory activities of the ligand and channels within the CNS. Although some PAMs are relatively non-selective, others have been reported to preferentially potentiate channels containing β2 subunits over those containing β1 subunits. In this study, we evaluated selective and non-selective PAMs, for their effects on HEK293 and CHO cells expressing GABAA α1β1γ2L and α1β2γ2L subtypes.
This poster is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related content from this organisation
- High-throughput screening: rapid advancements in drug discovery
- bit.bio raises $103 million in first close of Series B financing
- Cell-based assays market set to exhibit CAGR of 8.5 percent
- Under the microscope: CROs and microplate reader requirements
- Charles River Laboratories continues commitment to oncology drug discovery
Related organisations
Charles River Laboratories